Wall Street brokerages expect that Insmed Incorporated (NASDAQ:INSM – Get Rating) will post $58.83 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Insmed’s earnings. The highest sales estimate is $61.62 million and the lowest is $55.76 million. Insmed reported sales of $45.37 million in the same quarter last year, which suggests a positive year-over-year growth rate of 29.7%. The firm is expected to report its next earnings results on Monday, January 1st.
On average, analysts expect that Insmed will report full-year sales of $251.28 million for the current year, with estimates ranging from $245.10 million to $258.67 million. For the next fiscal year, analysts anticipate that the company will report sales of $342.90 million, with estimates ranging from $324.10 million to $375.29 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Insmed.
Insmed (NASDAQ:INSM – Get Rating) last announced its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.11. The company had revenue of $53.10 million for the quarter, compared to analysts’ expectations of $53.36 million. Insmed had a negative return on equity of 108.20% and a negative net margin of 217.35%. The business’s revenue for the quarter was up 32.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.89) earnings per share.
Shares of INSM stock opened at $18.19 on Monday. The stock’s fifty day moving average is $22.86 and its 200-day moving average is $25.06. The company has a debt-to-equity ratio of 6.73, a quick ratio of 5.52 and a current ratio of 6.04. The stock has a market capitalization of $2.17 billion, a PE ratio of -4.81 and a beta of 2.06. Insmed has a 52 week low of $16.41 and a 52 week high of $34.44.
In other Insmed news, Director Melvin Md Sharoky purchased 20,000 shares of the company’s stock in a transaction dated Wednesday, May 11th. The shares were bought at an average price of $17.20 per share, with a total value of $344,000.00. Following the completion of the transaction, the director now directly owns 262,621 shares in the company, valued at approximately $4,517,081.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO William Lewis sold 96,614 shares of the firm’s stock in a transaction dated Wednesday, March 23rd. The stock was sold at an average price of $23.16, for a total value of $2,237,580.24. The disclosure for this sale can be found here. Corporate insiders own 4.63% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Spire Wealth Management acquired a new stake in shares of Insmed during the fourth quarter worth about $27,000. Point72 Hong Kong Ltd acquired a new stake in shares of Insmed during the fourth quarter worth about $45,000. Advisor Group Holdings Inc. raised its position in shares of Insmed by 56.4% during the fourth quarter. Advisor Group Holdings Inc. now owns 2,140 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 772 shares during the period. Lindbrook Capital LLC bought a new position in shares of Insmed during the fourth quarter worth about $59,000. Finally, US Bancorp DE grew its holdings in shares of Insmed by 367.9% during the third quarter. US Bancorp DE now owns 2,569 shares of the biopharmaceutical company’s stock worth $70,000 after buying an additional 2,020 shares in the last quarter.
Insmed Company Profile (Get Rating)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
- Get a free copy of the StockNews.com research report on Insmed (INSM)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.